Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2018

View Archived Issues

MicroRNA-31-5p levels defines disease course and clinical outcome in Crohn's disease

Inhibition of hippocampal TLR2 signaling prevents Alzheimer's disease development

Dual GLP-1/GIP agonist LY-3298176 superior to GLP-1 agonist dulaglutide for diabetes control

NEO-PV-01 induces broad and durable immune responses in patients with metastatic cancers

GC-1118 shows promising efficacy in patients with CRC resistant to prior EGFR antibody therapy

Activating toxin early mitigates C. difficile infection

Forcing mutated cells to grow up

New ROCK2 inhibitor REDX-10178 shows promise for the treatment of kidney injury

FDA approves Xyrem for cataplexy or excessive daytime sleepiness in pediatric narcolepsy patients

FDA approves Bijuva for moderate to severe hot flashes due to menopause

Xtandi granted approval in Europe for high-risk nonmetastatic castration-resistant prostate cancer

Promising topline phase III data presented for Baxdela for treatment of CABP

NEC and Transgene sign MOU for cancer immunotherapy collaboration

Spark Therapeutics presents post-hoc analyses of phase III Luxturna data

Clearside Biomedical presents additional phase III data for Xipere in uveitic macular edema

Phase III study of daratumumab in front-line multiple myeloma meets primary endpoint

FDA allows IND for Athenex's oral eribulin

TMPRSS11E gene identified as a novel biomarker of smoking-related traits in Europeans

CS-1001 demonstrates promising preliminary safety and antitumor activity in phase I study

Preliminary data presented from phase I/II study of AGEN-1884 in combination with AGEN-2034

hNIS transgenic mouse as a resource of stem cells innately enabling in vivo cell tracking

CTAD 2018: Change in target? Maybe. Change in culture? Yes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...